Compare Estee Lauder Companies Inc (EL) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Eli Lilly And Co — how do they compare? Estee Lauder Companies Inc trades at $82.32 (market cap $29.78B), while Eli Lilly And Co trades at $1,176.68 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 34.6× Estee Lauder Companies Inc's market cap, and Estee Lauder Companies Inc pays the higher dividend (1.7%). Which is the better fit depends on your goals.
| EL | LLY | |
|---|---|---|
Market Cap | $29.78B | $1.03T |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $1.24K |
52-Week Low | $67.23 | $625.65 |
Enterprise Value | $35.95B | $1.07T |
Dividend Yield | 1.7% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $80.86, down 0.36% on the day, with a bearish technical signal and recent earnings beats. The stock shows a high P/E of 147.8 and negative net income margin of -1.67%, though revenue remains substantial at $14.33 billion for 2025. Recent news highlights innovation in beauty trends, but cash flow trends show net outflows over recent years.
Outlook is mixed: analyst consensus targets $90.60 with 44% buy ratings, but high valuation and profitability challenges pose risks. Recovery depends on margin improvement and sustained revenue growth amid competitive pressures.
Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.
Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
